Fig. 3: Secretome validation analysis. | Cell Death & Disease

Fig. 3: Secretome validation analysis.

From: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment

Fig. 3: Secretome validation analysis.The alternative text for this image may have been generated using AI.

A Bar plot showing fold-change expression of proteins identified in the secretome. B Bar plot showing protein levels of vimentin, EFEMP1 and C4BPA in FAPs secretome from healthy aged-matched controls (n = 4) and DMD patients (n = 6) analysed by ELISA. C Dot-plot showing EFEMP1 and C4BPA levels in serological samples from healthy aged-matched controls (n = 16) and DMD patients (n = 24) analysed by ELISA. Paired t-test was used to analyse. D Bar-plot showing the relative mRNA levels of C4BPA analysed in cells (n = 2). E Western-blot results of C4BPA and GAPDH expression in muscle tissue from healthy controls (n = 2) and DMD patients (n = 2), and in FAP cells from healthy controls (n = 3) and DMD patients (n = 4). F Representative images of muscle histology from a healthy control young boy and a DMD patient stained with C4BPA, laminin and PDGFRα. Scale bar: 50 µm. and bar plot showing the area of C4BPA expressed in the IF tissue staining from healthy controls (n = 3) and DMD patients (n = 3). Data are shown as means ± SD; Results were statistically analysed using paired t-test analysis. Statistical significance was set at P < 0.05; **P < 0.01; ***P < 0.001.

Back to article page